pipeline | autoimmune/inflammation | oncology
A Phase I healthy volunteer study for ALPN-101 is currently enrolling. ALPN-202 is targeted to file an IND or equivalent later in 2019.
We will have two posters at #SITC for ALPN-202, our conditional CD28 costimulator and dual checkpoint inhibitor (PD… twitter.com/i/web/status/11794…
October 2, 2019 6:00 pm
At this year’s #ACR19, we will have two ALPN-101 posters, one with preclinical data supporting #sjogrens and #lupus… twitter.com/i/web/status/11794…
October 2, 2019 4:52 pm
© 2019 Alpine Immune Sciences.
All Rights Reserved, Alpine Immune Sciences Inc.